Monoclonal antibodies: Materials
Materials it needs
The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is
Needs- Su Sugar criticality low The antibody-making cells are grown in nutrient media fed with sugars.
- Lys Amino acids (lysine, methionine) criticality low Cells need amino acids in their growth medium to build the antibody protein.
- Exc Pharmaceutical excipients criticality low Finished antibody medicines are formulated with stabilisers and buffers so they keep in the vial.
as of 2026-11-11. No source gives amounts per dose; the inputs are common, so criticality is the writer's judgement.
Critical materials
The materials whose supply could hold it back
- No raw material is likely to hold antibody medicines back: the cells are fed common sugars, salts and amino acids.
- The constraints are capacity and regulation: production needs licensed biologics plants, and each medicine is approved separately.
- Market concentration is high: in 2018 seven companies dominated the therapeutic antibody market, led by Genentech with about 30.8% and AbbVie with 20.0% [2].
as of 2026-11-11
Sources
- Development of therapeutic antibodies for the treatment of diseases Journal of Biomedical Science 27: 1 (Lu, Hwang, Liu, Lee, Tsai, Li and Wu), on PubMed Central, 2020